Arcturus Therapeutics (ARCT) Prices 1.365M Share Common Offering at $110/Sh
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 1,365,000 shares of its common stock at a public offering price of $110.00 per share. The gross proceeds of the offering to the Company are expected to be approximately $150 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 204,750 shares of common stock at the public offering price, less underwriting discounts and commissions.
The closing of the offering is expected to occur on or about December 10, 2020, subject to the satisfaction of customary closing conditions.
Piper Sandler & Co., Guggenheim Securities and Wells Fargo Securities are acting as joint book-running managers for the offering. Baird is acting as lead manager for the offering.
The Company intends to use the net proceeds of the offering to conduct clinical trials and to commence manufacturing its LUNAR-COV19 vaccine candidate for stockpiling purposes.